PRAME and metastatic melanoma: In a dose-escalation phase I study, we sought to determine an adequate dose of a recombinant PRAME protein (recPRAME, GSK, Belgium) administered with GSK's proprietary immunostimulant AS15, through evaluation of the safety and immunogenicity of the PRAME immunotherapeutic in patients with PRAME-positive metastatic melanoma.